Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Fig. 4

Selumetinib in combination with anti-CTLA-4 alters the composition of innate cells within tumors. On day 8 after initiation of anti-CTLA-4, selumetinib or combination treatment, cells were isolated from tumors and analysed by flow cytometry to identify and characterise myeloid cells and plasmacytoid DCs (pDC). a Gating strategy used to identify CD11b+Ly6G+Ly6CInt (I), CD11b+Ly6GLy6C+MHCIIlo/− (II), CD11b+Ly6GLy6C+MHCII+ (III), CD11b+Ly6GLy6CMHCIIlo/− (IV), CD11b+Ly6GLy6CMHCII+ (V) cells and CD11bB220+PDCA1+ pDCs. Phenotypic analysis of CD11c, PD-L1 and CD86 expression on cells are shown as histograms with matched isotype staining (black line) and target antigen staining (grey filled). b Frequencies of myeloid cells (I-V) and pDCs (VI) out of total CD45+ cells. Plotted are mean ± SD. Each group contained 8 mice. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Back to article page